Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.

Clicks: 330
ID: 265447
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #23 of 76 articles by views in The Pan African medical journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The treatment of chronic hepatitis C virus (HCV) infection in chronic hemodialysis patients remains an issue of great concern for nephrologists. In 2008 the kidney disease improving global outcomes working group suggested the use of pegylated interferon in end stage kidney disease patients treated by dialysis. Since then, series and some clinical trials on different direct-acting antiviral agents have shown better efficacy and tolerance than interferon-based regimens. Data on the efficacy, tolerance and the right dose of sofosbuvir in this population are still unclear. We report a case of chronic HCV genotype 1b infection in a 47-year-old patient on maintenance hemodialysis successfully treated by a combination of sofosbuvir and ledipasvir for 12 weeks. Evolution was marked by the complete regression of the hepatic cytolysis, a complete and sustained virologic response with HCV viral load undetectable for a 24 months follow-up period. No adverse reaction was found. The treatment of HCV genotype 1 or 4 infection in patients on maintenance hemodialysis is possible with sofosbuvir based regimens with a good efficacy/safety ratio in the absence of current recommended drugs for patients with eGFR<30ml/min/1.73m. The prescription of sofosbuvir should be encouraged amongst this population in this setting.
Reference Key
tchoupe2021treatmentthe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tchoupe, Marius Djoumbissie;Chaker, Hanen;Boudabbous, Mona;Toumi, Salma;Kissou, François Pegdebamba;Gargouri, Saba;Kammoun, Khawla;Jarraya, Faiçal;Tahri, Nabil;Yaich, Soumaya;Hmida, Mohamed Ben;
Journal The Pan African medical journal
Year 2021
DOI
10.11604/pamj.2021.38.137.20560
URL
Keywords
treatment hepatitis c hemodialysis case report sofosbuvir

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.